Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
- CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
- Acquisition of Neogene Therapeutics completed
Research & Development
- Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
- Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
- Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
- Power of cancer drugs may see boost by targeting newly ID'd pathway
- A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
- 500,000 missed out on blood pressure lowering drugs during pandemic
- Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease